{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:30:08Z","timestamp":1790515808720,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The review summarizes the current understanding of the role of hepcidin and ferroportin in normal iron homeostasis and its disorders. The various approaches to therapeutic targeting of hepcidin and ferroportin in iron-overload disorders (mainly hereditary hemochromatosis and \u03b2-thalassemia) and iron-restrictive anemias (anemias associated with infections, inflammatory disorders, and certain malignancies, anemia of chronic kidney diseases, and iron-refractory iron-deficiency anemia) are also discussed.<\/jats:p>","DOI":"10.1182\/asheducation-2011.1.538","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T20:33:13Z","timestamp":1323289993000},"page":"538-542","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":115,"title":["The Hepcidin-Ferroportin System as a Therapeutic Target in Anemias and Iron Overload Disorders"],"prefix":"10.1182","volume":"2011","author":[{"given":"Tomas","family":"Ganz","sequence":"first","affiliation":[{"name":"Department of Pulmonary & Critical Care Medicine, University of California-Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeta","family":"Nemeth","sequence":"additional","affiliation":[{"name":"Department of Pulmonary & Critical Care Medicine, University of California-Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111715483744800_B1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev-med-050109-142444","article-title":"Hepcidin and disorders of iron metabolism","volume":"62","author":"Ganz","year":"2011","journal-title":"Annu Rev Med"},{"key":"2019111715483744800_B2","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"key":"2019111715483744800_B3","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.24178","article-title":"Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice","volume":"53","author":"Ramos","year":"2011","journal-title":"Hepatology"},{"key":"2019111715483744800_B4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng1777","article-title":"Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression","volume":"38","author":"Babitt","year":"2006","journal-title":"Nat Genet"},{"key":"2019111715483744800_B5","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ng.320","article-title":"Lack of the bone morphogenetic protein BMP6 induces massive iron overload","volume":"41","author":"Meynard","year":"2009","journal-title":"Nat Genet"},{"key":"2019111715483744800_B6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/ng.335","article-title":"BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism","volume":"41","author":"Andriopoulos","year":"2009","journal-title":"Nat Genet"},{"key":"2019111715483744800_B7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/ng1274","article-title":"Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis","volume":"36","author":"Papanikolaou","year":"2004","journal-title":"Nat Genet"},{"key":"2019111715483744800_B8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cmet.2008.09.012","article-title":"The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin","volume":"8","author":"Silvestri","year":"2008","journal-title":"Cell Metab"},{"key":"2019111715483744800_B9","doi-asserted-by":"crossref","first-page":"28494","DOI":"10.1074\/jbc.C600197200","article-title":"Hereditary Hemochromatosis Protein, HFE, Interaction with Transferrin Receptor 2 Suggests a Molecular Mechanism for Mammalian Iron Sensing","volume":"281","author":"Goswami","year":"2006","journal-title":"J Biol Chem"},{"key":"2019111715483744800_B10","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood-2006-06-027631","article-title":"Interleukin-6 induces hepcidin expression through STAT3","volume":"108","author":"Wrighting","year":"2006","journal-title":"Blood"},{"key":"2019111715483744800_B11","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2215\/CJN.05931108","article-title":"Hepcidin\u2013a potential novel biomarker for iron status in chronic kidney disease","volume":"4","author":"Zaritsky","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019111715483744800_B12","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.hoc.2010.08.003","article-title":"Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in beta-thalassemia","volume":"24","author":"Gardenghi","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019111715483744800_B13","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1629","article-title":"High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin","volume":"13","author":"Tanno","year":"2007","journal-title":"Nat Med"},{"key":"2019111715483744800_B14","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI0215686","article-title":"The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation","volume":"110","author":"Nicolas","year":"2002","journal-title":"J Clin Invest"},{"key":"2019111715483744800_B15","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2008-02-139915","article-title":"Immunoassay for human serum hepcidin","volume":"112","author":"Ganz","year":"2008","journal-title":"Blood"},{"key":"2019111715483744800_B16","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/blood-2002-04-1260","article-title":"Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease","volume":"100","author":"Weinstein","year":"2002","journal-title":"Blood"},{"key":"2019111715483744800_B17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ng.130","article-title":"Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA)","volume":"40","author":"Finberg","year":"2008","journal-title":"Nat Genet"},{"key":"2019111715483744800_B18","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood-2005-10-4043","article-title":"Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System","volume":"108","author":"Tomosugi","year":"2006","journal-title":"Blood"},{"key":"2019111715483744800_B19","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/blood-2005-10-4071","article-title":"Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice","volume":"107","author":"Viatte","year":"2006","journal-title":"Blood"},{"key":"2019111715483744800_B20","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1172\/JCI41717","article-title":"Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice","volume":"120","author":"Gardenghi","year":"2010","journal-title":"J Clin Invest"},{"key":"2019111715483744800_B21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/blood-2008-03-146134","article-title":"The molecular basis of hepcidin-resistant hereditary hemochromatosis","volume":"114","author":"Fernandes","year":"2009","journal-title":"Blood"},{"key":"2019111715483744800_B22","article-title":"Analysis of the hepcidin-ferroportin interface yields minihepcidins, small peptides for the treatment of iron overload","author":"Preza","journal-title":"J Clin Invest"},{"key":"2019111715483744800_B23","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1053\/j.gastro.2010.07.044","article-title":"BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice","volume":"139","author":"Corradini","year":"2010","journal-title":"Gastroenterology"},{"key":"2019111715483744800_B24","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1182\/blood-2010-10-315507","article-title":"Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice","volume":"117","author":"Finberg","year":"2011","journal-title":"Blood"},{"key":"2019111715483744800_B25","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1182\/blood-2010-05-286260","article-title":"Detection, evaluation, and management of iron-restricted erythropoiesis","volume":"116","author":"Goodnough","year":"2010","journal-title":"Blood"},{"key":"2019111715483744800_B26","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood-2010-06-289082","article-title":"Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo","volume":"117","author":"Poli","year":"2011","journal-title":"Blood"},{"key":"2019111715483744800_B27","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood-2007-04-087593","article-title":"Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2\/4","volume":"110","author":"Lin","year":"2007","journal-title":"Blood"},{"key":"2019111715483744800_B28","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1182\/blood-2005-05-1845","article-title":"Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin","volume":"106","author":"Lin","year":"2005","journal-title":"Blood"},{"key":"2019111715483744800_B29","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1172\/JCI31342","article-title":"Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance","volume":"117","author":"Babitt","year":"2007","journal-title":"J Clin Invest"},{"issue":"18","key":"2019111715483744800_B30","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1182\/blood-2010-10-313064","article-title":"Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation","volume":"117","author":"Steinbicker","year":"2011","journal-title":"Blood"},{"key":"2019111715483744800_B31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nchembio.2007.54","article-title":"Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism","volume":"4","author":"Yu","year":"2008","journal-title":"Nat Chem Biol"},{"key":"2019111715483744800_B32","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1182\/blood-2010-03-271791","article-title":"Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease","volume":"116","author":"Song","year":"2010","journal-title":"Blood"},{"key":"2019111715483744800_B33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00296-009-1075-4","article-title":"Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production","volume":"30","author":"Hashizume","year":"2010","journal-title":"Rheumatol Int"},{"issue":"2","key":"2019111715483744800_B34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1365-2125.2011.03964.x","article-title":"Pharmacokinetics, pharmacodynamics, and safety of a human anti-IL-6 monoclonal antibody (Sirukumab) in healthy subjects in a first-in-human study","volume":"72","author":"Xu","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"2019111715483744800_B35","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00109-009-0588-3","article-title":"Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form","volume":"88","author":"Fatih","year":"2010","journal-title":"J Molec Med"},{"key":"2019111715483744800_B36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3324\/haematol.2009.013136","article-title":"Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin","volume":"95","author":"Ashby","year":"2010","journal-title":"Haematologica"},{"key":"2019111715483744800_B37","first-page":"49A","article-title":"Induction of erythropoiesis and iron utilization by the HIF prolyl hydroxylase inhibitor FG-4592 [Abstract]","volume":"16","author":"Klaus","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2019111715483744800_B38","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI31370","article-title":"Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)","volume":"117","author":"Peyssonnaux","year":"2007","journal-title":"J Clin Invest"},{"key":"2019111715483744800_B39","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2009-09-245977","article-title":"Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia","volume":"115","author":"Sasu","year":"2010","journal-title":"Blood"},{"key":"2019111715483744800_B40","first-page":"1011.6","article-title":"Identification of hepcidin antagonists through a high throughput screening approach [Abstract]","volume":"24","author":"Fung","year":"2011","journal-title":"FASEB J"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/538\/1492930\/bep00111000538.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/538\/1492930\/bep00111000538.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T20:48:54Z","timestamp":1574023734000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2011\/1\/538\/96430\/The-HepcidinFerroportin-System-as-a-Therapeutic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,10]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2011.1.538","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,10]]}}}